Delivery Order SPE2DB22D2103-SPE2DB25FR9UQ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) valued at $3,328.77. This firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive delivery against AmerisourceBergen's larger indefinite delivery contract with DLA. This delivery...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Janumet XR 50-1,000 mg tablets in quantities of 180 units. This contract represents a firm fixed-price delivery order valued at $21,902.08, with an ultimate completion date of September 2, 2025. The award was made competitively without set-aside restrictions and is being performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $19,423.78. This firm fixed-price delivery order represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX. The ultimate completion date for this delivery order is August 5,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) under a firm fixed-price arrangement. The $9,811.62 delivery order, which represents a non-set-aside competitive award, is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order through its established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $2,511.68. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. As a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,374.12 to AmerisourceBergen Drug Corp for the supply of Janumet XR 50-500 mg tablets (180-count unit) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger federal contracting relationship with DLA. The place of performance is located at the contractor's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180 count) with a ceiling value of $6,794.09. This competitive delivery order, issued under firm fixed price terms, represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the DLA. The place of performance is located at the vendor's corporate office in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order valued at approximately $61.2K to AmerisourceBergen Drug Corp for the supply of Janumet XR 50-1,000 mg tablets (180-count units). This contract, which was competitively awarded with no set-aside designation, became effective on July 24, 2025, with an ultimate completion date of July 25, 2025. The firm fixed-price delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,065.75 to AmerisourceBergen Drug Corp for 180-count supplies of Janumet XR 50-1,000 mg tablets. This was a competitively awarded, firm fixed-price delivery order with no set-aside designation, ultimately completed on August 20, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled the order from its corporate office location. This delivery order was issued...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $4,698.53. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive procurement. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 12, 2025. This delivery order is...
- SPE2DB22D2103Indefinite Delivery Contract
- SPE2DB22D2103-SPE2DB25FR9UQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $67,347.84 to AmerisourceBergen Drug Corp for the supply of Janumet XR 50-1,000 mg tablets (180-count units) on September 13, 2025, with a completion date of September 15, 2025. The award carries no set-aside designation and utilizes firm fixed pricing under a delivery order contract type. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive prime vendor contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Janumet XR, an antidiabetic combination medication, represents one product within the extensive pharmaceutical portfolio the contractor delivers through this strategic vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $67.3k | 9/13/25 |